Clinical trials
Muscular Dystrophy clinical trials
Below are recruiting muscular dystrophy clinical trials, each written for real people, not researchers. We’re tracking 137 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07125040Recruiting
Understanding LAMA2 muscle disease over time
This study follows people with LAMA2-related muscular dystrophy (a genetic muscle-weakening condition) to learn how it changes over time and find better ways to measure it. By participating, you help researchers identify new disease markers that could improve future treatments.
MilanAges Any age - NCT07573631Enrolling by invitationPhase 2
Long-term Safety Study of BMN 351 for Duchenne Muscular Dystrophy
This study continues treatment with an investigational medicine called BMN 351 for people with Duchenne muscular dystrophy (a genetic muscle-weakening condition). It checks whether the medicine remains safe and effective when used over a longer period, building on results from an earlier trial.
Milan, ItalyAges 4 years+ - NCT05933057RecruitingPhase 3
Givinostat for wheelchair-bound boys with Duchenne muscular dystrophy
This Phase 3 trial tests givinostat to see if it can improve safety and functional outcomes in boys with Duchenne muscular dystrophy who cannot walk. You might be a candidate if you meet age, genetic diagnosis, wheelchair-level mobility, and specific arm-strength/respiratory/heart criteria.
LeuvenAges 9–17 - NCT03882827Recruiting
Natural history study of Duchenne muscular dystrophy in young boys
This study follows boys with Duchenne muscular dystrophy over time to better understand how the condition changes and how standard treatments affect health and function. It does not appear to test a new medicine, but it may help doctors plan better future care and studies.
BrusselsAges 4–9 - NCT04012671Recruiting
Study of Duchenne muscular dystrophy in children and carriers
This is a research study that follows people with Duchenne muscular dystrophy and female genetic carriers to better understand the condition. It may help researchers measure health patterns over time, which can support future treatments.
FuzhouAges 2 years+ - NCT06402942Recruiting
Game-based occupational therapy for teens with Duchenne
This trial tests a fun, game-based occupational therapy program for teens with Duchenne muscular dystrophy. It aims to help you build skills and stay engaged through activities you can do at home on a computer or tablet.
AnkaraAges 13–18 - NCT06641895RecruitingEarly Phase 1
Testing BBM-D101 gene therapy for Duchenne muscular dystrophy
This early-phase study tests a new gene therapy called BBM-D101 for boys with Duchenne muscular dystrophy (DMD). The goal is to see if it is safe and helps improve muscle function in young boys.
Shanghai, Shanghai MunicipalityAges 4–8 - NCT06755138Recruiting
Scoliosis, pain, and quality of life in Duchenne muscular dystrophy
This study looks at how scoliosis (curved spine) and back pain affect daily life in people with Duchenne muscular dystrophy. Researchers will measure muscle strength and compensation patterns to understand these links.
SeoulAges 11–30 - NCT06773988Recruiting
Long-term monitoring of breathing support at home for Duchenne patients
This study follows adults with Duchenne muscular dystrophy who use a breathing machine (non-invasive ventilation or NIV) at home. It aims to track their health over time to improve care.
Leuven, Vlaams-BrabantAges 18 years+ - NCT06833489Recruiting
Using genetic testing to find answers for rare muscle diseases
This study looks at leftover muscle tissue from people who have had genetic testing for rare muscle diseases but didn't get a clear diagnosis. The goal is to use newer genetic analysis to find the cause of their disease.
MarseilleAges Any age - NCT06900049RecruitingEarly Phase 1
Testing LE051 for boys with Duchenne muscular dystrophy (exon 51)
This study tests a new medicine called LE051 for boys with Duchenne muscular dystrophy (DMD) who have a specific genetic change that allows 'exon 51 skipping.' The goal is to see if it is safe and can help improve muscle function. Boys who join will be closely monitored for heart and lung health.
Shanghai, Shanghai MunicipalityAges 4–8 - NCT07039799Recruiting
Virtual reality for arm function in Duchenne
This trial tests whether using virtual reality (VR) games can help improve arm and hand function in people with Duchenne muscular dystrophy. It may be a fun and engaging way to do exercises that strengthen your upper body.
Istanbul, FatihAges 7–18 - NCT07127978Recruiting
Study of Givinostat in people with Duchenne muscular dystrophy
This study is for people with Duchenne muscular dystrophy (DMD) who are taking Givinostat, a daily oral medicine. Researchers will look at real-world data to see how the medicine works in everyday life, including lab results and how it's being used.
Little Rock, ArkansasAges 6 years+ - NCT07286565Recruiting
Remote motor development study for early-diagnosed DMD or SMA
This study remotely tracks motor development in children with Duchenne muscular dystrophy or spinal muscular atrophy who were diagnosed at birth or before symptoms started. It aims to see if early monitoring helps improve long-term care and outcomes.
LiègeAges 4 months+ - NCT02069756Recruiting
Duchenne and Becker muscular dystrophy registry
This registry collects information about people with Duchenne or Becker muscular dystrophy, including women who carry the gene (with or without symptoms). It may help researchers better understand the condition and plan future studies.
Washington D.C., District of ColumbiaAges Any age - NCT07673809RecruitingPhase 1/Phase 2
Gene therapy trial for Duchenne muscular dystrophy in young boys
This trial tests a gene therapy called GNR-097 for boys with Duchenne muscular dystrophy (DMD). The therapy aims to help improve muscle function, and the study will check how safe and effective it is.
MinskAges 4–9 - NCT07629284Enrolling by invitation
Home-Based Breathing Therapy for Children With Duchenne Muscular Dystrophy
This study tests whether children with Duchenne muscular dystrophy (a genetic muscle-weakening condition) can improve their breathing strength and function by doing guided exercises at home using video calls with a therapist. The goal is to help children breathe better and stay as active as possible.
Seoul, SeoulAges 3 years+ - NCT07565272Enrolling by invitation
Virtual Reality Game for Duchenne Muscular Dystrophy Arm Strength
This study tests a video game played in virtual reality to see if it helps people with Duchenne muscular dystrophy (a muscle-weakening condition) use their arms and hands better. Researchers want to understand if the game is easy to use and enjoyable.
IstanbulAges 7 years+ - NCT07209332Enrolling by invitationPhase 2
Long-term safety study of WVE-N531 for Duchenne muscular dystrophy
This trial is for people who have already taken WVE-N531 in an earlier study. It continues to check the medicine's safety and effects over a longer period.
AmmanAges Any age - NCT06270719Enrolling by invitation
Comparing ELEVIDYS to standard care for Duchenne muscular dystrophy
This study compares the gene therapy ELEVIDYS (delandistrogene moxeparvovec) to usual treatments for people with Duchenne muscular dystrophy (DMD). It helps researchers understand how well ELEVIDYS works over time in real-world settings.
Little Rock, ArkansasAges 4 years+ - NCT06066580Enrolling by invitationPhase 2
Long-term sevasemten study for Becker muscular dystrophy
This trial offers continued treatment with sevasemten (EDG-5506) for people with Becker muscular dystrophy who already completed a previous study of this drug. It tests the long-term safety and effects of taking sevasemten over more time.
Little Rock, ArkansasAges Any age - NCT06131983RecruitingPhase 1/Phase 2
Study drug for facioscapulohumeral muscular dystrophy type 1
This trial is testing an investigational drug, SRP-1001, to see if it helps people with facioscapulohumeral muscular dystrophy type 1 (FSHD1), a condition that causes muscle weakness. The study will check if the drug is safe and if it can slow down the loss of muscle function.
Liverpool, New South WalesAges 16–70 - NCT05996003RecruitingPhase 2
Exon 44 skipping drug for Duchenne muscular dystrophy
This trial tests a new drug (NS-089/NCNP-02) that aims to help boys with Duchenne muscular dystrophy produce a shorter but still working version of the dystrophin protein. It's for boys who are still walking and have a specific genetic type that can be fixed by skipping a part of the gene called exon 44.
Aurora, ColoradoAges 4–14 - NCT06817382RecruitingPhase 1
Gene therapy for young boys with Duchenne muscular dystrophy
This study tests a one-time gene therapy given by injection into the spinal fluid (intrathecal) for boys with Duchenne muscular dystrophy. It aims to see if the treatment is safe and how it spreads in the body, and may offer a new way to slow the disease.
Little Rock, ArkansasAges 2–4
Hear when a new Muscular Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for muscular dystrophy?
- Yes. Clin2 currently lists 137 recruiting muscular dystrophy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a muscular dystrophy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a muscular dystrophy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.